Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
WALTHAM, Mass., May 01, 2017 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Deutsche Bank 42nd Annual Health Care Conference in Boston on Thursday, May 4, 2017 at 9:20 a.m. ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
[email protected]
